# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $26 p...
HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price...
Reaffirm the 2024 full-year total revenue guidance in the range of $455 million and $475 million.
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate...